Back

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

27 August 2018 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease Lipids Open Access ESC Congress 2018

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

4 More presentations in this session

Presentation thumbnail
Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment
Professor J. Jukema (Leiden, NL)
Slides Video
Presentation thumbnail
Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.
Professor D. Bhatt (New York City, US)

Access the full session

Session thumbnail
PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

The Event

Event poster

ESC Congress 2018

27 August 2018 13:05 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Session
Latest advancements in low-density lipoprotein cholesterol (LDL-C) lowering therapies and cardiovascular outcome trials
26 August 2023
thumbnail
Congress Presentation
Impact of lipoprotein(a) as a residual risk on long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statin
27 August 2021
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources